Skip to content
phase 2Cognitive & Neuro

PACAP

Also known as: Pituitary Adenylate Cyclase-Activating Polypeptide, PACAP-38, PACAP-27, ADCYAP1, Maxadilan-related peptide

PACAP (Pituitary Adenylate Cyclase-Activating Polypeptide) is a 38-amino acid neuropeptide belonging to the VIP-secretin-glucagon superfamily, originally isolated from ovine hypothalamus in 1989. It exists in two biologically active forms — PACAP-38 (predominant, 90% of brain PACAP) and PACAP-27 (truncated). PACAP is one of the most potent endogenous neuroprotective peptides identified, acting through PAC1, VPAC1, and VPAC2 receptors to activate cAMP/PKA and MAPK signaling. It is being actively investigated for stroke, traumatic brain injury, neurodegenerative diseases, migraine (as a migraine trigger and therapeutic target), and PTSD.

3 cited references·5 researched benefits

Quick Answer

PACAP is a 38-amino acid neuropeptide that is one of the most potent endogenous neuroprotective molecules discovered. Acting through PAC1, VPAC1, and VPAC2 receptors, it activates cAMP/PKA and MAPK signaling to promote neuronal survival, reduce inflammation, and support synaptic plasticity. Research shows strong neuroprotection in stroke and brain injury models. PACAP is also being studied for its role in migraine pathophysiology and as a biomarker for PTSD in women.

Key Facts

Mechanism
PACAP binds with high affinity to PAC1 receptors (specific to PACAP) and with equal affinity to VPAC1 and VPAC2 receptors (shared with VIP). PAC1 activation triggers multiple signaling cascades: adenylate cyclase activation produces cAMP, which activates protein kinase A (PKA) and EPAC — both promoting neuronal survival, synaptic plasticity, and gene expression changes. PAC1 also couples to phospholipase C (PLC), generating IP3 and diacylglycerol (DAG) for calcium signaling and PKC activation. Downstream effects include: upregulation of anti-apoptotic proteins (Bcl-2, Bcl-xL); suppression of caspase-3-mediated apoptosis; activation of CREB-mediated gene transcription (promoting BDNF expression); inhibition of microglial activation and pro-inflammatory cytokine release (IL-6, TNF-alpha); and enhancement of glutathione-mediated antioxidant defenses. PACAP is extremely potent, active at picomolar concentrations, but has a very short plasma half-life (~3–5 minutes) due to rapid degradation by dipeptidyl peptidase IV (DPP-IV) and other peptidases.
Research Status
phase 2
Half-Life
~3–5 minutes (plasma); tissue effects persist through downstream signaling cascades
Molecular Formula
C₂₀₃H₃₃₃N₅₇O₅₃S₁
Primary Use
Cognitive & Neuro
Table of Contents

Benefits

  • Potent neuroprotection in stroke — dramatically reduces infarct volume and neuronal death in animal models of ischemic and hemorrhagic stroke, with a therapeutic window of several hours post-injurystrong
  • Traumatic brain injury recovery — reduces secondary brain damage, neuroinflammation, and cognitive deficits following TBI in preclinical modelsmoderate
  • Anti-neuroinflammatory — potently suppresses microglial activation and pro-inflammatory cytokine production, addressing a key driver of neurodegeneration and secondary brain injurystrong
  • Neurodegenerative disease protection — protects dopaminergic neurons in Parkinson's models and reduces amyloid-beta toxicity in Alzheimer's disease modelspreliminary
  • PTSD biomarker and therapeutic target — blood PACAP levels correlate with PTSD symptoms in women, and PACAP/PAC1 signaling modulates fear conditioning and stress response circuitrymoderate

Dosage Protocols

RouteDosage RangeFrequencyNotes
Intravenous infusion (research/clinical)10–20 pmol/kg/minContinuous infusion over 20 minutesResearch dosing used in migraine provocation studies and cardiovascular research. This is NOT a therapeutic dosing recommendation. The very short half-life (~3–5 min) requires continuous infusion for sustained effects.
Intranasal (experimental)Not establishedUnder investigationIntranasal delivery is being explored to achieve CNS effects while minimizing systemic vasodilation and migraine triggering. Stabilized PACAP analogs with longer half-lives are in preclinical development for this route.
Intracerebroventricular (preclinical)1–10 nmol (animal dosing)Single or repeated injectionsDirect brain administration used in preclinical neuroprotection studies to bypass peripheral degradation and side effects. Not applicable to human clinical use.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Migraine induction — PACAP-38 infusion reliably triggers migraine attacks in migraine sufferers, which has been extensively used in migraine research; this limits systemic administrationserious
  • Vasodilation and flushing — potent vasodilator that causes facial flushing, warmth, and transient hypotension via smooth muscle relaxation and mast cell degranulationcommon
  • Heart palpitations — increases heart rate through direct cardiac effects and reflex tachycardia from vasodilationcommon
  • Gastrointestinal effects — stimulates gastric acid secretion, pancreatic exocrine function, and intestinal motility; may cause nausea, cramping, or diarrhearare
  • Very short half-life — rapid degradation by DPP-IV limits therapeutic utility of native PACAP and necessitates continuous infusion or stabilized analogscommon

Frequently Asked Questions

If PACAP triggers migraines, how can it be neuroprotective?
This apparent paradox reflects PACAP's complex biology. PACAP triggers migraines through peripheral mechanisms — vasodilation of meningeal arteries, mast cell degranulation, and sensitization of trigeminal sensory neurons. Its neuroprotective effects, however, are mediated centrally through PAC1 receptor activation in neurons, promoting survival signaling and anti-inflammatory pathways. The therapeutic challenge is achieving CNS neuroprotection without triggering peripheral migraine-related effects. Strategies being developed include targeted CNS delivery (intranasal, intrathecal), PAC1-selective agonists that avoid VPAC receptors involved in vasodilation, and modified PACAP analogs with reduced peripheral activity.
What is the connection between PACAP and PTSD?
A landmark 2011 study (Ressler et al., Nature) found that blood PACAP-38 levels are significantly elevated in women with PTSD, and that a single nucleotide polymorphism in the PAC1 receptor gene (ADCYAP1R1) is associated with PTSD risk specifically in women. This was the first peptide biomarker identified for PTSD. PACAP modulates the amygdala fear circuitry and hypothalamic-pituitary-adrenal (HPA) stress axis — systems central to PTSD pathophysiology. The sex-specific nature of this association relates to estrogen regulation of PACAP and PAC1 expression. This discovery has opened new avenues for PTSD diagnostics and PAC1-targeted therapeutics.
How does PACAP relate to VIP (Vasoactive Intestinal Peptide)?
PACAP and VIP share 68% amino acid sequence homology and both activate VPAC1 and VPAC2 receptors. They likely evolved from a common ancestral gene. The key difference is that PACAP additionally activates the PAC1 receptor, which VIP does not — and PAC1 is the primary mediator of PACAP's neuroprotective effects. PACAP is generally considered more potent as a neuroprotectant due to this PAC1 selectivity. In clinical practice, VIP is used as a therapeutic for pulmonary hypertension and has been studied for inflammatory bowel disease, while PACAP research focuses more on neurological applications.
Are stable PACAP analogs being developed for clinical use?
Yes, several approaches are in development to overcome PACAP's 3–5 minute half-life. These include: DPP-IV-resistant PACAP analogs with modified N-terminal residues; PEGylated PACAP formulations for extended circulation time; lipidated PACAP derivatives for depot injection; PAC1-selective agonists that retain neuroprotection without vasodilation; and nanoparticle and liposomal PACAP delivery systems. Maxadilan, a PAC1-specific agonist derived from sand fly saliva, has also been studied as a template for designing selective PACAP receptor agonists. These are all in various stages of preclinical development.

References

  1. 1
    Pituitary adenylate cyclase activating polypeptide (PACAP) — discovery and current state of research(1989)PubMed ↗
  2. 2
    PACAP signaling in neuroprotection, neuroinflammation, and neurodegeneration: comprehensive review(2015)PubMed ↗
  3. 3
    Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor in women(2011)PubMed ↗

Latest Research

Last updated: 2026-02-19